# HAIC Plus H101 vs HAIC Alone for Unresectable HCC at BCLC A-B

> **NCT03780049** · PHASE3 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 304 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **PROCEDURE:** HAIC of FOLFOX
- **DRUG:** H101
- **DRUG:** Placebos

## Key facts

- **NCT ID:** NCT03780049
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-10-01
- **Primary completion:** 2023-10-01
- **Final completion:** 2023-10-01
- **Target enrollment:** 304 (ESTIMATED)
- **Last updated:** 2020-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03780049

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03780049, "HAIC Plus H101 vs HAIC Alone for Unresectable HCC at BCLC A-B". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03780049. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*